Mylan, Pfizer settle patent suit on generic Detrol LA

Fri Sep 7, 2012 5:35pm IST

Stocks

   

(Reuters) - Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.

Mylan can start selling its generic versions of Pfizer's drug from January 1, 2014, or earlier under some limited circumstances, but not after March 1, 2014, if the U.S. Food and Drug Administration approves.

Terms of the settlement are subject to review by the Federal Trade Commission and the U.S. Department of Justice, and other details are confidential, Mylan said.

The settlement with Mylan comes days after Pfizer resolved a similar dispute with Impax Laboratories Inc late last month.

(Reporting by Zeba Siddiqui in Bangalore; Editing by Akshay Lodaya)

"India's Daughter"

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage